Overview

Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled, 4-period, cross-over clinical trial. The study is designed to evaluate the safety and local tolerability of DA-6034 upon single and repeated-dose topical application to the both eyes in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Dong-A ST Co., Ltd.
Treatments:
Ophthalmic Solutions
Tetrahydrozoline